Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05783492
Other study ID # 113103
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date January 1, 2024
Est. completion date April 30, 2024

Study information

Verified date November 2018
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial (Intranasal ketamine for procedural sedation in children: a randomized controlled non-inferiority multicenter trial or INK; ReDA 5496; CTO 1545) is being scheduled for launch in Spring 2019. Due to the possibility of failure of the experimental intervention (intranasal ketamine 10 mg/kg), the data safety monitoring board (DSMB) and statistical methods team would like to explore the possibility of developing a stopping rule to prevent patients from being enrolled in a futile trial and conserve resources. In order to get accurate data to develop a statistically robust stopping rule, it is necessary to conduct a cohort study of patients that receive the INK trial's experimental intervention and according to it's protocol. This cohort study will help estimate the chance of adequate sedation and inform the final dosing protocol for the INK trial.


Description:

Between 20 and 40% of extremity fractures in children require a closed reduction, often necessitating procedural sedation and analgesia (PSA) (3, 4). Intravenous (IV) ketamine is the most commonly used sedative agent used to perform a closed reduction (5). However, children rate IV insertion as the most painful hospital experience, second only to the injury itself (6). Intranasal (IN) ketamine may provide effective sedation for children undergoing a closed reduction without the distress and pain related to IV insertion. Although the proportion of children with adequate sedation using IN ketamine at doses of 9-10 mg/kg has been reported to be at least 75% (9-11), there is the possibility of inadequate sedation because IN ketamine 10 mg/kg has not been used for procedural sedation for fracture reduction. A multi-centre, two-arm, randomized, blinded, controlled, non-inferiority trial designed to test the hypothesis that intranasal (IN) ketamine is non-inferior to intravenous (IV) ketamine is being planned for launch in Spring 2019 and a stopping rule for futility will ensure that patients are not unduly enrolled and that resources are not wasted in a futile trial. Creating of a methodologically rigorous stopping rule depends on the results of a small cohort study to provide a more accurate and informed estimate of the probability of adequate sedation with IN ketamine 10 mg/kg.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 30, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 7 Years to 17 Years
Eligibility Inclusion Criteria: - General Criteria 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Deemed by treating physician to require procedural sedation using ketamine Specific Criteria 1. Children presenting to the paediatric EDs of participating sites age 7-17 years 2. Weighing up to and including 80 kg 3. Distal radius +/- ulna fracture or dislocation of a shoulder, elbow, patella, or digit 4. Closed reduction expected to take no more than 5 minutes to reduce (as determined by the procedure physician and not including cast or splint application). Exclusion Criteria: - 1) Previous hypersensitivity reaction to ketamine including rash, difficulty breathing, hypotension, apnea, or laryngospasm; 2) Suspected globe rupture; 3) Concomitant traumatic brain injury with intracranial hemorrhage; 4) Uncontrolled hypertension; 5) Nasal bone deformity or nasal obstruction with at least one nare obstructed due to allergic or viral rhinitis, sinusitis, nasal polyps, or septal deviation; 6) Poor English or French fluency in the absence of native language interpreter; 7) American Society of Anesthesiologists (ASA) class 3 or greater; 8) Previous diagnosis of schizophrenia or active psychosis as per the treating physician 9) Neuro-cognitive impairment that precludes informed consent, assent, or ability to self-report pain and satisfaction; 10) Multi-limb trauma; 11) Hemodynamic compromise as per the treating physician; 12) Glasgow coma score < 15; 13) Previous sedation with ketamine within 24 hours; 14) Fracture is comminuted or associated with a dislocation; 15) Participant has undergone a hematoma block within 24 hours; 16) Isolated ulna fracture; 17) Previous enrollment in the trial; 18) Suspected pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intranasal ketamine
10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Lawson Health Research Institute

Outcome

Type Measure Description Time frame Safety issue
Primary Adequacy of sedation Dartmouth Operative Conditions Scale (DOCS) score between -2 and +2 for the duration of the closed reduction AND, (ii) No additional IV ketamine is given during closed reduction for the purpose of sedation, AND (iii) The patient did not actively resist, cry, or require physical restraint for completion of the closed reduction. 1 hour
Secondary Length of stay Defined as the time recorded in the medical record between triage and discharge in minutes 1 hour
Secondary Onset of sedation This will be defined as the time interval from administration of the first pair of IN sprays to the time when a first DOCS score of between -2 and +2 is achieved post-intervention (minutes) 1 hour
Secondary Duration of sedation This will be defined as the duration of time between the first DOCS score between -2 to +2 post-intervention to the last DOCS score between -2 and +2 post-closed reduction (minutes). 1 hour
Secondary Adverse effects Research nurses will be trained on the recognition and definition of expected and unexpected AEs. AEs will be determined from the medical record and recorded on REDCap. Expected AEs are based on the Quebec guidelines and other practice guidelines. Unpleasant recovery reactions will be recorded by the research nurse using REDCap. 1 hour
See also
  Status Clinical Trial Phase
Recruiting NCT03692390 - Virtual Reality vs. Standard-of-Care for Comfort Before and After Sedation in the Emergency Department N/A
Completed NCT02145169 - Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study N/A
Recruiting NCT05595798 - EEG Spectral Pattern of Deep Sedation-induced Airway Adverse Effects
Completed NCT01260662 - Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Phase 4
Completed NCT00784498 - Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department Phase 4
Completed NCT00327392 - A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. Phase 2/Phase 3
Recruiting NCT04873596 - Dexmedetomidine and Midazolam Nebulization as Sedation During Cesarean Delivery in Pre-eclampsia Phase 2
Completed NCT03329014 - A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability Phase 1
Recruiting NCT06414395 - The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study Phase 4
Recruiting NCT03860831 - Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities: Phase 1
Completed NCT00869440 - Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 2
Not yet recruiting NCT05757622 - Electroencephalogram Based Real-Time Sedation Level Prediction
Completed NCT03799783 - The Use of Dexmedetomidine for EEG Sedation in Children With Behavioural Disorders Phase 2
Completed NCT02180737 - Dexmedetomidine for Sedation During Radiological Interventional Procedures Phase 4
Not yet recruiting NCT01227174 - Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery Phase 4
Recruiting NCT03499886 - Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique Phase 2/Phase 3
Completed NCT03747432 - Comparison of Procedural Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation Phase 4
Recruiting NCT06203522 - Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin
Recruiting NCT04686448 - Ketofol Versus Fenofol as Procedural Sedation for Carpal Tunnel Release Phase 1/Phase 2
Completed NCT02955732 - Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients Phase 4